Difference between revisions of "Concluding Remarks section from DOI: 10.3390/pathogens9020148 (Q7907)"

From Wikibase.slis.ua.edu
Jump to navigation Jump to search
(‎Created claim: has part (P22): Item:Q7902, #quickstatements; #temporary_batch_1585881482185)
 
(5 intermediate revisions by the same user not shown)
label / enlabel / en
-
Concluding Remarks (Main section from DOI: 10.3390/pathogens9020148)
+
Concluding Remarks section from DOI: 10.3390/pathogens9020148
description / endescription / en
-
Publication: "Emergence of Novel Coronavirus 2019-nCoV: Need for Rapid Vaccine and Biologics Development" in the MDPI journal Pathogens (2020); DOI: 10.3390/pathogens9020148
+
Main section in the article "Emergence of Novel Coronavirus 2019-nCoV: Need for Rapid Vaccine and Biologics Development" in the MDPI journal Pathogens (2020); DOI: 10.3390/pathogens9020148
Property / has part
-
Q7902 (Deleted Item)
 
Property / has part: Q7902 (Deleted Item) / rank
-
Normal rank
 
Property / followed by
 +
Property / followed by: Table 1 - Advantages and disadvantages of different therapeutic protein production platforms (From DOI: 10.3390/pathogens9020148) / rank
 +
Normal rank
Property / IMRaD(C) Section
 +
Property / IMRaD(C) Section: Conclusion / rank
 +
Normal rank
Property / follows
 +
Property / follows: Perspectives on Biopharmaceuticals Development section from DOI: 10.3390/pathogens9020148 / rank
 +
Normal rank

Latest revision as of 20:07, 13 April 2020

Main section in the article "Emergence of Novel Coronavirus 2019-nCoV: Need for Rapid Vaccine and Biologics Development" in the MDPI journal Pathogens (2020); DOI: 10.3390/pathogens9020148
Language Label Description Also known as
English
Concluding Remarks section from DOI: 10.3390/pathogens9020148
Main section in the article "Emergence of Novel Coronavirus 2019-nCoV: Need for Rapid Vaccine and Biologics Development" in the MDPI journal Pathogens (2020); DOI: 10.3390/pathogens9020148

    Statements